接受内分泌治疗、内分泌治疗加帕博西尼或化疗的 HR+/HER2- 转移性乳腺癌女性患者总生存期的真实世界比较

{"title":"接受内分泌治疗、内分泌治疗加帕博西尼或化疗的 HR+/HER2- 转移性乳腺癌女性患者总生存期的真实世界比较","authors":"U. Rizwan, R. Hussain, G. Kanagala","doi":"10.1016/j.ejca.2024.113714","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":505596,"journal":{"name":"European Journal of Cancer","volume":"114 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Comparison of Overall Survival in Female Patients with HR+/HER2- Metastatic breast cancer receiving endocrine therapy, endocrine therapy plus palbociclib, or chemotherapy\",\"authors\":\"U. Rizwan, R. Hussain, G. Kanagala\",\"doi\":\"10.1016/j.ejca.2024.113714\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":505596,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"114 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ejca.2024.113714\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ejca.2024.113714","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}